RESUMEN
Pulmonary mucormycosis is a life-threatening infection caused by a fungus that is part of the Mucorales family. Diabetes ketoacidosis has been classically described as the main risk factor for the disease. Tracheobronchial mucormycosis is an infrequent form of pulmonary mucormycosis that presents as a tracheobronchial tumor obstructing the airway. Few cases have been reported in the literature. We present a case of pulmonary mucormycosis that presented initially as a collapsed right upper lung, mimicking a tracheobronchial tumor. Early detection and treatment are key to avoid fatal outcomes.
RESUMEN
INTRODUCTION: Aside from examination for Clostridium difficile, the yield of stool testing in hospital-onset diarrhea is poor. Clinical practice guidelines discourage overzealous stool testing in patients with diarrhea that develops after the third hospital day. However, the adoption of this recommendation into clinical practice is limited. Furthermore, the effect of microbiology laboratory improvements on hospital-onset diarrhea testing is largely unknown. METHODS: A retrospective cohort study was conducted in a university-affiliated community-hospital and included all adult inpatients who developed diarrhea after hospitalization. RESULTS: 132 adult patients (53% female) developed diarrhea after hospitalization in 2013. The cohort's mean age was 55.6 years. 46.2% of patients developed diarrhea in the first 3 days of hospitalization. Testing for parasites was negative in all examined 67 samples. Testing for C. difficile was positive in 13 cases (10.8%) out of 120 tested samples. Testing for other pathogens was positive in 1 sample (Campylobacter) out of 129 samples. Stool samples tested in the first 3 days of hospitalization were more likely to be positive (64.3 vs 35.7%, p = 0.1). Change in management was reported in 9 out of 14 patients (64.3%) with positive stool testing compared with 31 out of 118 patients (26.3%) with negative stool testing, p = 0.01. CONCLUSION: Despite improvements in stool samples' testing, the yield continues to be low, especially in hospital-onset diarrhea past the third hospital day. Physicians' embracement of the '3-day rule' continues to be poor.
Asunto(s)
Infección Hospitalaria/microbiología , Diarrea/microbiología , Heces/microbiología , Hospitalización/estadística & datos numéricos , Adulto , Anciano , Clostridioides difficile/aislamiento & purificación , Estudios de Cohortes , Infección Hospitalaria/epidemiología , Diarrea/epidemiología , Humanos , Pacientes Internos/estadística & datos numéricos , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Salmonella enteritidis/aislamiento & purificación , Factores de TiempoRESUMEN
BACKGROUND: Antibiotic de-escalation is a potential strategy advocated to conserve the effectiveness of broad-spectrum antibiotics. The aim of this study was to examine the safety and feasibility of antibiotic de-escalation in patients admitted with bacteremic pneumonia. METHODS: A retrospective chart review was done for patients with bacteremic pneumonia admitted to Northwest Texas Hospital in Amarillo, TX, USA, during 2008. Antibiotic de-escalation was defined as changing the empiric antibiotic regimen to a culture-directed single agent with a narrower spectrum than the original regimen. RESULTS: Sixty-eight patients were admitted with bacteremic pneumonia. Eight patients were not eligible for de-escalation. Among the 60 patients who were eligible for de-escalation, the treating physicians failed to de-escalate antibiotics in 27 cases (45.0%). Discharge to a long-term care facility predicted failure to de-escalate antibiotics, while an infectious diseases consultation was significantly associated with antibiotic de-escalation. The average daily cost of antibacterial therapy in the de-escalation group was $25.7 compared with $61.6 in the group where de-escalation was not implemented. The difference in mean length of hospital stay and mortality between the two groups was not statistically significant. CONCLUSION: Antibiotic de-escalation is a safe management strategy but unfortunately is not widely adopted. Although bacterial resistance poses a significant threat and is rising, antimicrobial de-escalation has emerged as a potential intervention that can conserve the effectiveness of broad-spectrum antibiotics without compromising the patient's outcome. This practice is becoming important in the face of slow development of new anti-infective agents.